---
document_datetime: 2025-01-30 11:51:30
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/flucelvax-tetra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: flucelvax-tetra-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 7.1505746
conversion_datetime: 2025-12-28 10:53:12.561204
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Flucelvax Tetra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| II/0047              | Extension of indication to include treatment of adults and children from 6 months of age and older for FLUCELVAX TETRA based on final results from study V130_14. This is a phase 3, randomized, observer- blind, multicenter study to evaluate the efficacy, immunogenicity, and safety of Seqirus' Cell-Based | 12/12/2024                          | 23/01/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion Flucelvax Tetra EMEA/H/C/004814/II/0047 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | Quadrivalent Subunit Influenza Virus Vaccine (QIVc) compared to a non-influenza vaccine when administrated in healthy subjects aged 6 months through 47 months. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.3 of the RMP has also been approved. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10737 /202403 | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 03/10/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0045             | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                                                                                                                                                                                                                                                                                                                                                                   | 11/07/2024 | 24/07/2024 | SmPC, Labelling and PL | As a result of this variation, Section 2 of the SmPC (qualitative and quantitative composition) has been updated to reflect the changes in Influenza strains included in the NH 2024/2025 formulation as follows: • A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022, CVR-167) • A/Massachusetts/18/2022 (H3N2)-like strain (A/Sydney/1304/2022, wild type) • B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) • B/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type) |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                        | The Labelling and PL and Annex A have been updated accordingly.                                                                                                                                                                                                               |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044 | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the | 22/02/2024 | n/a        |                        |                                                                                                                                                                                                                                                                               |
| II/0041 | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability                                                                                                                                                                                                               | 14/12/2023 | n/a        |                        |                                                                                                                                                                                                                                                                               |
| IB/0043 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                | 11/12/2023 | n/a        |                        |                                                                                                                                                                                                                                                                               |
| R/0040  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                     | 12/10/2023 | 07/12/2023 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Flucelvax Tetra in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| II/0039             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol   | 09/11/2023   | n/a        |                        |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IB/0042             | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                    | 24/10/2023   | n/a        |                        |                                   |
| PSUSA/10737 /202303 | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                                                    | 28/09/2023   | n/a        |                        | PRAC Recommendation - maintenance |
| II/0037             | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                 | 06/07/2023   | 24/07/2023 | SmPC, Labelling and PL |                                   |
| N/0036              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 17/05/2023   | 24/07/2023 | PL                     |                                   |
| IB/0034             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                 | 10/05/2023   | n/a        |                        |                                   |
| IA/0035             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                | 14/04/2023   | n/a        |                        |                                   |
| IB/0033/G           | This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits                                                                                                                                                          | 09/02/2023   | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|         | applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0030 | Update of section 4.8 of the SmPC in order to add Guillain Barré syndrome (GBS) to the list of adverse drug reactions (ADRs) based on the assessment of the global safety database. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to carry out minor updates to the Package Leaflet to fully align it with the information in the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 09/02/2023 | 24/07/2023 | SmPC and PL | As a possible relationship between GBS and Flucelvax Tetra cannot be excluded, and there is at least a reasonable possibility to consider a causal association between GBS and Flucelvax Tetra, Section 4.8 of the SmPC was updated to include Guillain Barré syndrome (GBS) to the list of adverse drug reactions (ADRs), with frequency 'not known'. |
| II/0031 | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol                                                                                                                                                                                                                     | 15/12/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                        |
| II/0029 | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                                                                                                                                                        | 01/12/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| PSUSA/10737 /202203   | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                                                                                                                                                               | 29/09/2022   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027               | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                                                                                                                            | 07/07/2022   | 27/07/2022 | SmPC, Labelling and PL | As a result of this variation, Section 2 of the SmPC (qualitative and quantitative composition) has been updated to reflect the changes in Influenza strains included in the NH 2022/2023 formulation. For NH 22/23 influenza season, the following influenza strains have been included: • A/Delaware/55/2019 CVR-45 (H1N1), an A/Wisconsin/588/2019 (H1N1) pdm09-like virus • A/Darwin/11/2021 (H3N2), an A/Darwin/6/2021 - like virus • B/Singapore/WUH4618/2021 (B-Victoria), a B/Austria/1359417/2021 - like virus • B/Singapore/INFTT-16-0610/2016 (B-Yamagata), a B/Phuket/3073/2013 - like virus The Labelling, Package leaflet and Annex A have been updated accordingly. |
| II/0025/G             | This was an application for a group of variations. B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile medicinal products B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for | 24/03/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                        |                                                                                                                                                                                                                                                                                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                             | 17/02/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                  |
| IA/0026             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                      | 14/02/2022 | n/a        |                        |                                                                                                                                                                                                                                                                                                                  |
| II/0023             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                  | 13/01/2022 | 27/07/2022 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10737 /202103 | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                          | 30/09/2021 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                |
| II/0021             | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                       | 08/07/2021 | 23/07/2021 | SmPC, Labelling and PL | As a result of this variation, Section 2 of the SmPC (qualitative and quantitative composition) has been updated to reflect the changes in Influenza strains included in the NH 2021/2022 formulation. The virus strains included in the vaccine for the season 2021-2022 are: • A/Washington/19/2020 (H1N1) (an |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                               |            |            |                 | type • A/Tasmania/503/2020 (H3N2) (an A/Cambodia/e0826360/2020-like strain), wild type • B/Singapore/INFTT-16-0610/2016 (B-Yamagata) (a B/Phuket/3073/2013 - like strain), wild type • B/Darwin/7/2019 (B-Victoria) (a B/Washington/02/2019 - like strain), wild type Labelling and Package leaflet are updated accordingly.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0020   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                 | 03/03/2021 | 23/07/2021 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                |
| IB/0019   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                  | 05/02/2021 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                |
| IA/0018/G | This was an application for a group of variations. B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier | 01/12/2020 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                |
| II/0017   | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a                                                                                                                                            | 12/11/2020 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | biological/immunological product                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                 |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------|
| II/0013             | Extension of the indication of prophylaxis of influenza, from the currently approved age range \"adults and children from 9 years of age\" to \"adults and children from 2 years of age\" for Flucelvax Tetra; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been approved. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 17/09/2020 | 22/10/2020 | SmPC and PL            | Please refer to Scientific Discussion 'Flucelvax Tetra EMEA/H/C/004814/II/0013' |
| PSUSA/10737 /202003 | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                                                                                                                                                                                                                                                                                                     | 01/10/2020 | n/a        |                        | PRAC Recommendation - maintenance                                               |
| II/0014             | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                                                                                                                                                                                                                                                                  | 10/07/2020 | 27/07/2020 | SmPC, Labelling and PL |                                                                                 |
| IB/0016             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                  | 24/06/2020 | n/a        |                        |                                                                                 |

<div style=\"page-break-after: always\"></div>

| IB/0011             | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                             | 03/04/2020   | n/a        |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------------------------------|
| IAIN/0012           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                       | 06/03/2020   | n/a        |                        |                                   |
| IAIN/0009/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 06/03/2020   | 27/07/2020 | SmPC, Labelling and PL |                                   |
| II/0008             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                    | 28/11/2019   | n/a        |                        |                                   |
| PSUSA/10737 /201903 | Periodic Safety Update EU Single assessment - influenza vaccine (surface antigen, inactivated, prepared in cell cultures)                                                                                                                                                                                                                                | 03/10/2019   | n/a        |                        | PRAC Recommendation - maintenance |
| II/0007             | B.I.a.5.a - Changes to the AS of a seasonal, prepandemic or pandemic vaccine against human influenza - Replacement of the strain(s) in a seasonal, prepandemic or a pandemic vaccine against human influenza                                                                                                                                             | 09/08/2019   | 23/08/2019 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| II/0003   | B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method                                                                                                                                              | 27/06/2019   | 23/08/2019   | Annex II and PL        |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-------------|
| II/0004/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change approved specifications limits range | 23/05/2019   | n/a          |                        | outside the |
| IAIN/0005 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                        | 26/04/2019   | 23/08/2019   | SmPC, Labelling and PL |             |
| IB/0002   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                      | 27/02/2019   | 23/08/2019   | SmPC, Labelling and PL |             |
| IB/0001   | B.II.g.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                      | 12/02/2019   | n/a          |                        |             |